Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Advanced Biomed Inc. - Common Stock
BancFirst Corporation - Common Stock
Certara, Inc. - Common Stock
Cresco Labs Inc
Dare Bioscience, Inc. - Common Stock
Energy and Water Development Corp
First Trust NASDAQ Cybersecurity ETF
Integral Ad Science Holding Corp. - Common Stock
Myseum.AI, Inc. - Common Stock
OSI Systems, Inc. - Common Stock
Orbsat Corp - Common Stock
Ryzon Materials Limited
SEALSQ Corp - Ordinary Shares
Sigyn Therapeutics Inc
Silex Sys Ltd Spon ADR
Suncor Energy Inc. Common Stock
VanEck HIP Sustainable Muni ETF
XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock
iShares Morningstar Multi-Asset Income ETF
Edit Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Odyssey Therapeutics, Inc. - Common Stock
(NQ:
ODTX
)
19.60
+0.52 (+2.73%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Odyssey Therapeutics, Inc. - Common Stock
Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026
October 20, 2026
From
Odyssey Therapeutics Inc
Via
GlobeNewswire
Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026
October 12, 2026
Topline induction results expected in the second half of 2027
From
Odyssey Therapeutics Inc
Via
GlobeNewswire
Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026
October 06, 2026
From
Odyssey Therapeutics Inc
Via
GlobeNewswire
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
September 16, 2026
From
Odyssey Therapeutics Inc
Via
GlobeNewswire
Odyssey Therapeutics to Participate in Upcoming Investor Conferences
August 26, 2026
From
Odyssey Therapeutics Inc
Via
GlobeNewswire
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 04, 2026
From
Odyssey Therapeutics Inc
Via
GlobeNewswire
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
June 17, 2026
From
Odyssey Therapeutics Inc
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
